Enlivex
Paul J. Martin, M.D., is a board-certified oncologist at SCCA, a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center and a UW professor of Medicine and Oncology, served as the Medical Director of Clinical Research Support, the Fred Hutch Clinical Trials Office, from 2011 to 2017. He is a Member of the Fred Hutch and a Professor of Medicine at the UW.
Dr. Martin has more than 35 years of experience with hematopoietic cell transplantation at Fred Hutch, focusing on acute and chronic graft-versus-host disease (GVHD).
He has contributed to the field through several large retrospective studies of GVHD as well as prospective clinical trials for treatment or prevention of chronic GVHD.
Dr. Martin earned his M.D. at the University of Pennsylvania. He is board certified in both Internal Medicine and Medical Oncology. His clinical and research interests include bone marrow transplantation and chemotherapeutic agents. He is the SCCA lead investigator for the US-ATG-F to Prevent Chronic Graft Versus Host Disease clinical trial.
This person is not in the org chart
This person is not in any offices
Enlivex
Enlivex's mission is to establish new equilibriums – both in patients’ immune responses and in the field of immunotherapy. As a clinical-stage company focused on specialized cell immunotherapy, Enlivex intends to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses.